By USFDA to Rhizen Pharmaceuticals SA (an associate company)
Alembic Pharmaceuticals announced that its associate company, Rhizen Pharmaceuticals SA has been granted by USFDA Fast Track Designation for RP6530 (tenalisib), a highly dual PI3K delta/gamma inhibitor for the treatment of patients with relapsed / refractory peripheral T-cell lymphoma.Powered by Capital Market - Live News
Disclaimer: No Business Standard Journalist was involved in creation of this content
